Mirum Pharmaceuticals Initiates Rolling Submission of a New Drug Application for Maralixibat for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome and Launches Expanded Access Program
FOSTER CITY, Calif.--(BUSINESS WIRE)--Sep. 1, 2020-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases today...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news
More News: Drugs & Pharmacology | Liver | Liver Disease | New Drug Applications | Urology & Nephrology